Cafepharma Today

May 22 2025 - Sanofi inks $470M Vigil buyout, brushing off rivals' failures to join Novartis in Alzheimer's race
Sanofi inks $470M Vigil buyout, brushing off rivals' failures to join Novartis in Alzheimer's race
FDA advisors unanimously snub Pfizer's Talzenna in broader prostate cancer population
Prices for new US drugs doubled in 4 years as focus on rare disease grows
FDA expands warnings of heart risks on COVID shots
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Will Abbott Laboratories Disappoint Analysts Next Quarter?
Motley Fool
Saturday, May 28, 2011 - 12:11pm
tags:
Abbott Laboratories
Eli Lilly Dividend, Cash Flow Safe Despite Patent Cliff: Barclays
Barron's
Saturday, May 28, 2011 - 12:10pm
tags:
Eli Lilly
Johnson & Johnson Unveils Revitalized Pipeline
Seeking Alpha
Saturday, May 28, 2011 - 12:08pm
tags:
JNJ, pipelines
A Hidden Reason Why Eli Lilly's Earnings Are Outstanding
Motley Fool
Saturday, May 28, 2011 - 12:07pm
tags:
Eli Lilly, earnings
What Kind of Phase 2 Drug Can You Get for $5 Million?
Motley Fool
Saturday, May 28, 2011 - 12:06pm
tags:
Cell Therapeutics
Don't Believe the Obesity Hype
Motley Fool
Saturday, May 28, 2011 - 12:03pm
tags:
weight loss, obesity, Arena Pharmaceuticals
FDA Approves Optimer's DIFICID (fidaxomicin) Tablets for the Treatment of Patients with Clostridium difficile-Associated Diarrhea (CDAD)
Yahoo/PR NewsWire
Saturday, May 28, 2011 - 12:01pm
tags:
Clostridium Difficile, C. difficile, Optimer, Dificid
Arena, Orexigen and Vivus: An Update on Their Obesity Drugs
Seeking Alpha
Saturday, May 28, 2011 - 12:00pm
tags:
Arena Pharmaceuticals, Orexigen, Vivus, obesity, Qnexa, weight loss, Contrave
Trimeris gets $5M in Roche settlement
bizjournals.com
Saturday, May 28, 2011 - 11:58am
tags:
Trimeris, Roche, Fuzeon
Millennium and Seattle Genetics Announce Brentuximab Vedotin (SGN-35) Presentations at 16th Congress of the European Hematology Association
Yahoo/BusinessWire
Saturday, May 28, 2011 - 11:56am
tags:
Millennium, Seattle Genetics, brentuximab vedotin, SGN-35, Hodgkin's lymphoma
China-Biotics and Sinovac Biotech Benefit From China's Biotech Revolution
Yahoo/MarketWire
Saturday, May 28, 2011 - 11:54am
tags:
China-Biotics, Sinovac Biotech
Biotech Stock Mailbag: Fibrocell Science
The Street
Saturday, May 28, 2011 - 11:52am
tags:
Fibrocell Science, laViv, dermal fillers, Botox
AZ: No more free trips for doctors
Fierce Pharma
Friday, May 27, 2011 - 12:11pm
tags:
AstraZeneca, David Brennan, physicians
J&J Now the “Best Biotech Play”, Says Goldman
Barron's
Friday, May 27, 2011 - 12:09pm
tags:
JNJ, biotech, Abbott Laboratories
Cutting Up Pfizer May Just Make a Big Mess
Seeking Alpha
Friday, May 27, 2011 - 11:32am
tags:
Pfizer, reorganization
Investors Should Take Notice of Congressional Questions Regarding Nuedexta Pricing
Seeking Alpha
Friday, May 27, 2011 - 10:54am
tags:
investors, Nuedexta, PBA, Avanir, drug pricing
Full Steam Ahead for Spectrum Pharmaceuticals
Seeking Alpha
Friday, May 27, 2011 - 10:52am
tags:
Spectrum Pharmaceuticals, Teva Pharmaceuticals
A Hidden Reason Why Eli Lilly's Earnings Are Outstanding
Motley Fool
Friday, May 27, 2011 - 10:51am
tags:
Eli Lilly, earnings
It May Be Time for Amylin and Lilly to Head to Divorce Court
Seeking Alpha
Friday, May 27, 2011 - 10:50am
tags:
Eli Lilly, Amylin, restraining order, Alkermes, Bristol-Myers Squibb, Elan, GSK, JNJ, Lexicon Pharmaceuticals, Novo Nordisk, Takeda
The Supreme Court & How To Delay Generics, Pt. 2
Pharmalot
Friday, May 27, 2011 - 9:10am
tags:
generics, Supreme Court, Hatch Waxman Act

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline
Lose Your Crystalline Form and Go Amorphous
In the Pipeline
Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.